SoftOx Solutions AS — Regulatory Filings 2021

Feb 3, 2021

SoftOx Solutions AS and the Norwegian Defence Research Establishment (FFI) sign letter of intent

SoftOx Solutions AS and the Norwegian Defence Research Establishment (FFI) sign letter of intent

SoftOx Solutions AS and the Norwegian Defence Research Establishment (FFI) have signed a letter of intent with a plan to adapt the civilian products the company develops to be used for military purposes. SoftOx Solutions AS currently provides hand and surface disinfection products without alcohol that possess different and unique properties than current products on the market. The company is also working on the development of a wound wash product, a product that prevents and removes wound infections and a product for the treatment of viral infections in the respiratory tract.

The parties are now working towards the goal of signing a 3–5-year collaboration agreement by 1 April 2021. If the research and development collaboration (R&D) is signed in April, the parties will together carry out basic research, testing and experimentation of SoftOx products to identify the effects of different products for the operational capability of the Armed Forces. “We want the collaboration to contribute to improving the availability of operational personnel in exercises and operations and ensure the best possible prevention and treatment of wounds and infectious injuries that occur in the Armed Forces' operations,” according to CEO Geir Almås of SoftOx Solutions.

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS

Mail: geir.almaas@soft-ox.com

Mobile: +47 977 59 071

About SoftOx Solutions AS

SoftOx Solutions AS (Softx, listed on the Euronext Growth, Oslo)

is a Norwegian BioTech company based in Oslo with the aim of helping to combat

major threats to human health, namely the emergence of antimicrobial resistance

(AMR), biofilm infections in chronic wounds and the spread of viruses. For more

information on SoftOx, visit www.soft-ox.com